Article Sidebar
Views PDF: 3
ASSOCIATION BETWEEN DISEASE TYPE AND CLINICAL, PARACLINICAL CHARACTERISTICS, AND DISEASE STAGE IN PATIENTS WITH MULTIPLE MYELOMA
Main Article Content
Abstract
Objective: This study aims to examine the relationship between disease type and clinical, paraclinical characteristics, as well as disease stage, in patients diagnosed with multiple myeloma (MM) at Military Hospital 103 from January 2016 to December 2024. Subjects and Methods: A cross-sectional descriptive study was conducted on 98 patients diagnosed with MM at Military Hospital 103. Results: The majority of patients had the IgG disease type (53.1%), followed by IgA (28.6%), Light Chain (12.2%), and other types (6.1%). Statistically significant differences were observed between disease types in median values of age, white blood cell count, platelet count, bone marrow plasmocyte ratio, and hemoglobin level group (p < 0.05). Similarly, variations in albumin concentration, Beta-2 Microglobulin levels, and ISS disease stage were also found among different disease types, with p-values of 0.016, 0.039, and 0.04, respectively. Among them, IgA had the highest proportion of patients with albumin levels below 35 g/L (85.7%), whereas Light Chain had the highest proportion with albumin ≥ 35 g/L (66.7%). Regarding ISS disease stage: IgG was most commonly observed in stage ISS II (57.7%), while IgA had the highest proportion in stage ISS III (50%). Conclusion: Disease type is associated with age, peripheral blood cell indices and ISS disease stage in patients with MM.
Article Details
Keywords
Multiple Myeloma, Types of Multiple Myeloma, Military Hospital 103
References
2. Wang W, Zhang C-X, Li Z-L, et al. Detection of intracellular IgD using flow cytometry could be a novel and supplementary method to diagnose IgD multiple myeloma. BMC Cancer. 2018; 18:1-5.
3. Liu J, Hu X, Jia Y, et al. Clinical features and survival outcomes in IgD myeloma: A study by Asia Myeloma Network (AMN). Leukemia. 2021; 35(6):1797-1802.
4. Sirohi B, Powles R, Kulkarni S, et al. Comparison of new patients with Bence-Jones, IgG, and IgA myeloma receiving sequential therapy: The need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria. Bone Marrow Transplantation. 2001; 28(1):29-37.
5. Bal S, Giri S, Godby KN, et al. Revisiting the impact of immunoglobulin isotypes in multiple myeloma. Annals of Hematology. 2022; 101(4):825-829.
6. Wang L, Jin F-Y, Li Y, S et al. IgA type multiple myeloma, clinical features, and prognosis. Chinese Medical Journal. 2018; 131(10):1249-1250.
7. Chu N-L, Zhang J-Y, Guo L, et al. Expression and clinical significance of IL-6, IL-10, TNF-α and β2-MG in multiple myeloma patients with different results of blood separation. Zhongguo shi yan xue ye xue za zhi. 2020; 28(5):1625-1630.
8. Argyropoulos CP, Chen SS, Ng Y-H, et al. Rediscovering beta-2 microglobulin as a biomarker across the spectrum of kidney diseases. Frontiers in Medicine. 2017; 4:73.
9. Sindhu ER, Das AY, Padmanabhan M, et al. Correlation of plasma cell percentage and monoclonal gammapathies with biochemical parameters in multiple myeloma patients: A retrospective study. Asian Pacific Journal of Cancer Care. 2023; 8(4):685-689.
10. Torres H, Martínez R, González J. Correlation between β2-microglobulin, grobulin levels & the number of plasmatic cells in patients with multiple myeloma. Int J Biomed Res Prac. 2021; 1(2):1-4.